Martingale Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Martingale Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,809	Closed	-$513K	–	817
2024 Q3	$513K	Buy	12,809 +4	+0%	+$186	0.01%	619
2024 Q2	$610K	Sell	12,805 -510	-4%	-$20.9K	0.01%	561
2024 Q1	$577K	Buy	13,315 +3	+0%	+$143	0.01%	593
2023 Q4	$673K	Sell	13,312 -722	-5%	-$34.6K	0.01%	536
2023 Q3	$637K	Hold	14,034	–	–	0.01%	557
2023 Q2	$576K	Buy	14,034 +91	+0.7%	+$3.5K	0.01%	586
2023 Q1	$498K	Buy	13,943 +3,582	+35%	+$135K	0.01%	618
2022 Q4	$391K	Buy	10,361 +648	+7%	+$27.3K	0.01%	671
2022 Q3	$431K	Buy	9,713 +2,308	+31%	+$97.2K	0.01%	645
2022 Q2	$275K	Hold	7,405	–	–	0.01%	749
2022 Q1	$275K	Buy	+7,405	New	+$242K	﹤0.01%	743

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Martingale Asset Management's IONS Position: Q4 2024 in Review

Martingale Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2024, closing a stake of 12,809 shares — an estimated $513K sold.

Martingale Asset Management first reported a position in IONS in Q1 2022 and held it in 11 quarters. The position peaked at $673K in Q4 2023. 354 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

Martingale Asset Management reported no remaining Ionis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Martingale Asset Management sold 12,809 Ionis Pharmaceuticals shares in Q4 2024, an estimated $513K.
Martingale Asset Management first reported a position in Ionis Pharmaceuticals in Q1 2022 and held it in 11 quarters.
Martingale Asset Management's Ionis Pharmaceuticals position peaked at $673K in Q4 2023.
354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on Martingale Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.